Details

Autor(en) / Beteiligte

• Kohn, Donald B
• Dotti, Gianpietro
• Brentjens, Renier
• Savoldo, Barbara
• Jensen, Michael
• Cooper, Laurence JN
• June, Carl H
• Rosenberg, Steven
• Sadelain, Michel
• Heslop, Helen E

Titel

CARs on Track in the Clinic

Ist Teil von

• Molecular therapy, 2011-03, Vol.19 (3), p.432-438

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2011

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Chimeric antigen receptors (CARs) are fusion proteins between single-chain variable fragments (scFv) from monoclonal antibodies recognizing tumor-associated antigens and intracellular signaling domains such as the CD3 [zeta]-chain cytoplasmic tail. Transduction of peripheral blood T lymphocytes with these targeting moieties confers specific cytotoxic immunoreactivity against cells expressing the target epitope. These agents have shown high activity in preclinical models of immunotherapy, and several sites are studying them clinically. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Subcommittee on Cell and Gene Therapy convened a meeting of the investigators in the United States performing phase I clinical trials using CARs targeting CD19 on B-lineage malignancies, as well as representatives from the National Institutes of Flealth (NIH), to review the state of the science and to discuss the challenges to be overcome to advance these agents to multicenter trials. This article summarizes those discussions and highlights the promises of this approach to immunotherapy.